Holen Sie sich die Stockscreener-App
49.61
2.17%
-1.10
Schlusskurs vom Vortag:
$50.71
Offen:
$50.69
24-Stunden-Volumen:
818.91K
Relative Volume:
1.27
Marktkapitalisierung:
$2.39B
Einnahmen:
Nettoeinkommen (Verlust:
$-86.97M
KGV:
-20.51
EPS:
-2.4189
Netto-Cashflow:
$-81.88M
1W Leistung:
-6.82%
1M Leistung:
-19.43%
6M Leistung:
+49.34%
1J Leistung:
+260.28%
1-Tages-Spanne:
$49.23
$50.88
1-Wochen-Bereich:
$47.60
$54.03
52-Wochen-Spanne:
$12.94
$72.64
Mbx Biosciences Inc Stock (MBX) Company Profile
Firmenname
Mbx Biosciences Inc
Sektor
Branche
Telefon
(317) 989-3100
Adresse
11711 N. MERIDIAN STREET, CARMEL
Compare MBX vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
49.61 | 2.39B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-21 | Fortgesetzt | JP Morgan | Overweight |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-12-04 | Eingeleitet | Goldman | Sell |
| 2025-11-04 | Eingeleitet | TD Cowen | Buy |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-08-15 | Fortgesetzt | Jefferies | Buy |
| 2025-08-05 | Eingeleitet | Mizuho | Outperform |
| 2025-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-10 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | JP Morgan | Overweight |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
Alle ansehen
Mbx Biosciences Inc Aktie (MBX) Neueste Nachrichten
MBX S-8及美國證券交易委員會申報文件 - Yahoo 財經
MBX Biosciences (NasdaqGS:MBX) Stock Forecast & Analyst Predictions - Simply Wall Street
MBX Biosciences (Nasdaq:MBX)Stock Analysis - simplywall.st
MBX Biosciences, Inc. (MBX) stock price, news, quote and history - Yahoo Finance Singapore
MBX Biosciences to Participate in Upcoming Investor Conferences - marketscreener.com
MBX Biosciences will present in New York and online - Stock Titan
MBX Biosciences, Inc. Announces Appointment of Jeff Held as Chief Legal Officer - marketscreener.com
MBX Biosciences, Inc. (MBX) stock price, news, quote and history - au.finance.yahoo.com
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer - The Manila Times
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer - Yahoo Finance
Lawyer who co-led a $2.4B acquisition joins MBX Biosciences - stocktitan.net
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer - GlobeNewswire
MBX Biosciences Share Price Chart (MBX) - Investing.com UK
MBX Biosciences (MBX) Is Down 7.5% After Starting Phase 3 oPTimize Trial – Has The Bull Case Changed? - simplywall.st
MBX Q2 2026 Earnings: Wider-than-Expected Loss Pressures SharesEarnings Stability Report - vinanet.vn
MBX Biosciences (MBX), Why Is It Getting So Much Attention Now? - sahmcapital.com
MBX Biosciences doses first patient in phase 3 HP trial - Investing.com
MBX Biosciences doses first patient in phase 3 HP trial - Investing.com India
MBX Biosciences doses first patient in phase 3 HP trial By Investing.com - Investing.com Nigeria
MBX Biosciences (MBX) Slips 2.7% to $66.76, Holding Above Key Support at $63.42Sign of Weakness - dars.gov.et
MBX Biosciences Insiders Added US$1.06m Of Stock To Their Holdings - moomoo.com
MBX BIOSCIENCES, INC. : JP MORGAN RESUMES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $88 - Bitget
JPMorgan Chase & Co. Initiates Coverage on MBX Biosciences (NASDAQ:MBX) - MarketBeat
J.P. Morgan Maintains MBX Biosciences(MBX.US) With Buy Rating, Announces Target Price $88 - moomoo.com
Deep Track Capital Reduces MBX Biosciences Stake in Strategic Pr - GuruFocus
MBX (MBX) Move: Finishes 2.76% Lower at $66.51 on the Day; Technical View: the Supplied Trading Band Runs From $63.18 to $69.84 on the DayMean Reversion Trade - vinanet.vn
MBX (MBX) Move: Finishes 2.76% Lower at $66.51 on the Day; Technical View: the Supplied Trading Band Runs From $63.18 to $69.84 on the DayFibonacci Extension - siam.in
MBX (MBX) Snapshot: Finishes 0.13% Lower at $66.44 on the Day; Boundary Watch: $63.12 and $69.76 Define the Nearby Reference Levels for the Current SessionBollinger Squeeze - vinanet.vn
MBX Biosciences (NASDAQ: MBX) insider to sell 3,745 shares - Stock Titan
MBX Biosciences (MBX) Edges Lower to $68.12, Consolidating Between Support and ResistanceZigzag Correction - vinanet.vn
MBX Q2 2026 Earnings: Wider-than-Expected -$0.78 Loss Highlights Accelerated Pipeline InvestmentRevenue Estimate Trend - vinanet.vn
MBX Biosciences (MBX) Edges Lower to $68.12, Consolidating Between Support and ResistanceStop Run - dars.gov.et
MBX Biosciences Inc (MBX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
California State Teachers Retirement System Purchases 21,011 Shares of MBX Biosciences, Inc. $MBX - MarketBeat
Deep Track Capital reports 3.64% MBX Biosciences (MBX) stake in 13G/A - stocktitan.net
Stifel Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $70 - Moomoo
MBX Biosciences (MBX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Frazier funds detail 10.8% MBX Biosciences stake (MBX) in ownership update - Stock Titan
OrbiMed trims MBX Biosciences (MBX) position to 6.4% after share sales - Stock Titan
Truist Adjusts Price Target on MBX Biosciences to $88 From $70, Maintains Buy Rating - Moomoo
MBX Biosciences, Inc. $MBX Stock Holdings Raised by The Manufacturers Life Insurance Company - MarketBeat
LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $121 - moomoo.com
MBX Biosciences (NASDAQ:MBX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Mizuho Securities Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $91 - Moomoo
MBX SWOT Analysis: Financial Challenges and Growth Potential Rev - GuruFocus
Barclays Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $88 - Moomoo
MBX Biosciences (MBX) Stock Analysis: Strong Buy Ratings and Significant Upside Potential - DirectorsTalk Interviews
MBX Biosciences, Inc. Stock 12‑Month Price Target Raised to $84.8, Implies 26% Upside - TradingView
MBX Biosciences Shares Lower After Q2 Loss Widens - marketscreener.com
MBX Biosciences Shares Lower After Q2 Loss Widens - Yahoo Finance
Finanzdaten der Mbx Biosciences Inc-Aktie (MBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mbx Biosciences Inc-Aktie (MBX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Azoulay Salomon | Officer |
Aug 04 '26 |
Proposed Sale |
65.77 |
370 |
24,336 |
0 |
| Azoulay Salomon | Chief Medical Officer |
Aug 04 '26 |
Sale |
65.77 |
370 |
24,335 |
14,399 |
| Hawryluk P. Kent | Officer |
Aug 04 '26 |
Proposed Sale |
65.77 |
936 |
61,563 |
0 |
| Bartram Richard | Former Officer |
Jun 10 '26 |
Proposed Sale |
30.55 |
9,167 |
280,010 |
0 |
| Bartram Richard | Former Officer |
Jun 09 '26 |
Proposed Sale |
29.66 |
10,833 |
321,273 |
0 |
| Bartram Richard | Former Officer |
May 13 '26 |
Proposed Sale |
36.95 |
15,000 |
554,296 |
0 |
| Bartram Richard | Former Officer |
May 11 '26 |
Proposed Sale |
44.08 |
22,500 |
991,901 |
0 |
| Azoulay Salomon | Officer |
May 08 '26 |
Proposed Sale |
38.37 |
70,003 |
2,685,679 |
0 |
| Azoulay Salomon | Chief Medical Officer |
May 08 '26 |
Option Exercise |
11.65 |
70,003 |
815,348 |
69,769 |
| Bartram Richard | Former Officer |
May 08 '26 |
Proposed Sale |
37.96 |
10,000 |
379,562 |
0 |
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):